Pacira BioSciences Falls After Preliminary Sales Miss Estimates

Dow Jones01-09

By Katherine Hamilton

Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates.

The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months.

The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet.

Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected.

Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said.

For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million.

Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 08, 2026 18:10 ET (23:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602531672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602531672","market":"sg","top_or_hot":-1,"title":"Pacira BioSciences Falls After Preliminary Sales Miss Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates. \n</p>\n<p>\n  The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months. \n</p>\n<p>\n  The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet. \n</p>\n<p>\n  Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected. \n</p>\n<p>\n  Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said. \n</p>\n<p>\n  For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million. \n</p>\n<p>\n  Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacira BioSciences Falls After Preliminary Sales Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacira BioSciences Falls After Preliminary Sales Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 07:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates. \n</p>\n<p>\n  The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months. \n</p>\n<p>\n  The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet. \n</p>\n<p>\n  Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected. \n</p>\n<p>\n  Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said. \n</p>\n<p>\n  For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million. \n</p>\n<p>\n  Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602531672","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602531672","pubTimestamp":1767913800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates.The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months.The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet.Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected.Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said.For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million.Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"Pacira BioSciences因初步销售额未达预期而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates. \n\n\n  The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months. \n\n\n  The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet. \n\n\n  Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected. \n\n\n  Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said. \n\n\n  For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million. \n\n\n  Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 18:10 ET (23:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602531672","isCrawlerRequest":true}